Learning Objectives After completing this course, the reader will be able to: Explain the
mechanism of action of a recently approved new cancer drug, pemetrexed. Describe the adverse-…

… Only a small number of patients with progressive disease during first-line therapy had
stable disease during treatment with ALIMTA. In conclusion, ALIMTA has shown activity in two …

Pemetrexed (Alimta ® ) is a novel, multitargeted antifolate that inhibits at least three of the
enzymes involved in folate metabolism, and purine and pyrimidine synthesis. These enzymes …

Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three
enzymes involved in the folate pathway. These enzymes are thymidylate synthase, …

Zhao, Goldman 243 thymidylate relative to purine biosynthesis might actually enhance the
activity of this agent [8]. There are unique properties of pemetrexed that distinguish it from …

… resistance to Alimta was possibly due to Alimta’s ability to inhibit several folate-dependent
reactions. By analyzing end-product reversal patterns, Schultz hypothesized that Alimta has a …

… paper new and efficient novel syntheses of Alimta (1) and TNP-351 (4), and the application
of this new method to syntheses of homo and nonbridged analogues of Alimta (1) as well as …

Purpose To determine the safety and activity of LY231514 (ALIMTA™, MTA, pemetrexed
disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced …

Pemetrexed is a new member of the antifolate class of anticancer drugs. Here we describe
how it is activated, its mode of action and its pharmacokinetics. Three single-agent Phase I …

Background To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naïve
patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and …